Cell Based NIPT using ARCEDI technology explained in 90 seconds

ARCEDI Biotech ApS aims at achieving the goal of ‘Non-invasive Prenatal Testing’ (NIPT) based on fetal cells enriched from pregnant women’s blood.

The perspective for ARCEDI technology is to develop a no risk method of providing pregnant women with accurate information about the genetic status of their unborn child. The solution, based on simple blood sampling, provided by ARCEDI holds the potential to replace the current invasive procedures, known to induce unintended abortions.

The potential use of fetal cells in NIPT is well acknowledged. However, because of the rarity of these cells in maternal circulation, limited knowledge of the cell type, and the absence of specific markers to enrich the fetal cells, has hindered the development of cell-based NIPT.

For the last 10 years ARCEDI Biotech addressed these issues. The scientific team at ARCEDI was the first to describe that extravillous trophoblasts are the fetal cell type that circulate in maternal blood (1) and also used markers against these cells to successfully enrich them from the blood (2). In a recent publication in ‘Prenatal Diagnosis’, scientists at ARCEDI, among others, have described an improved method of enriching fetal cells and have also used 1-2 fetal cells to perform chromosomal and subchromosomal testing without invasive sampling (3). This is one of the first studies to report successful genetic analysis on fetal cells enriched from maternal blood.

Recently ARCEDI has secured a US patent on the markers for isolating fetal cells (Patent No. 9429520).

Taking this knowledge further ARCEDI is currently performing a clinical validation study on ‘high risk’ pregnancies. This will enable a comparison of results from cell based analysis with the results from cell free NIPT and CVS.

REFERENCES

  1. Hatt L., Brinch M., Singh R., Møller K., Lauridsen RH., Uldbjerg N., Huppertz B., Christensen B., Kølvraa S. (2014). Characterization of Fetal Cells from the Maternal Circulation by Microarray Gene Expression Analysis – Could the Extravillous Trophoblasts Be a Target for Future Cell-Based Non-Invasive Prenatal Diagnosis? Fetal Diagnosis and Therapy. 35: 218-227.
  2. Hatt L., Brinch M., Singh R., Møller K., Lauridsen RH., Schlutter JM., Uldbjerg N., Christensen B., Kølvraa S. (2014). A new marker set that identifies fetal cells in maternal circulation with high specificity. Prenatal Diagnosis. 34 (11): 1066-1072.
  3. Kølvraa S., Singh R., Normand E., Qdaisat S., Van den Veyver I.B., Jackson L., Hatt L., Schelde P., Uldbjerg N., Vestergaard E.M., Zhao L., Chen R., Shaw C., Bremen A., Beaudet A. (2016). Genome-wide copy number analysis on DNA from fetal cells isolated form the blood of pregnant women. Prenatal Diagnosis (In Press)